(Q45128212)

9 December 2017

title

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib (English)

1 reference

Carlo Gambacorti-Passerini

9 December 2017

1 reference

7

1 reference

9 December 2017

Piazza RG

1

1 reference

9 December 2017

Magistroni V

2

1 reference

9 December 2017

Gasser M

3

1 reference

9 December 2017

Andreoni F

4

1 reference

9 December 2017

Galietta A

5

1 reference

9 December 2017

Scapozza L

6

1 reference

9 December 2017

R G Piazza

1

0 references

V Magistroni

2

0 references

M Gasser

3

0 references

F Andreoni

4

0 references

A Galietta

5

0 references

L Scapozza

6

0 references

C Gambacorti-Passerini

7

0 references

publication date

1 January 2005

1 reference

9 December 2017

28 October 2004

0 references

published in

Leukemia

1 reference

9 December 2017

volume

19

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

132-134

1 reference

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

9 December 2017

cites work

2 references

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403928

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403453

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2403928

1 reference

Dimensions Publication ID

9 December 2017

10.1038/SJ.LEU.2403453

0 references

1051012097

0 references

1 reference